A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

September 9, 2020

Study Completion Date

October 11, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

Etrasimod 1 mg

Etrasimod 1 mg tablet taken by mouth, once daily

DRUG

Etrasimod 2 mg

Etrasimod 2 mg tablet taken by mouth, once daily.

DRUG

Etrasimod matching placebo

Etrasimod matching placebo tablet by mouth, once daily.

Trial Locations (38)

2217

Premier Specialists PTY LTD, Kogarah

3002

Sinclair Dermatology, East Melbourne

10012

Greenwich Village Dermatology, New York

23220

Clinical Research Partners, LLC, Richmond

23507

Alliance for Multispecialty Research, Norfolk

29369

Spartanburg Medical Research, Spartanburg

30291

Rophe Adult and Pediatric Medicine/SKYCRNG, Union City

33016

Aby's New Generation Research, Inc., Hialeah

33021

Skin Care Research, LLC, Hollywood

33030

Advanced Research Institute of Miami LLC, Homestead

Amber Pediatrics Research, LLC, Homestead

33138

Amber Clinical Research, LLC, Miami Shores

33155

South Miami Medical & Research Group. Inc, Miami

33166

Prohealth Research Center, Doral

33169

Amber Pediatrics Research, LLC, Miami

33173

Skin Research of South Florida, Miami

33603

Clinical Research of West Florida, Inc., Tampa

33709

IMA Clinical Research, LLC, St. Petersburg

33765

Clinical Research of West Florida, Clearwater

39157

Quinn Healthcare/SKYCRNG, Ridgeland

40217

Skin Sciences PLLC, Louisville

57702

Health Concepts, Rapid City

68114

Quality Clinical Research Inc, Omaha

75231

Modern Research Associates, PLLC, Dallas

76550

FMC Science, Lampasas

77702

Gadolin Research, Beaumont

78626

FMC Science, Georgetown

85704

Noble Clinical Research, Tucson

89109

Excel Clinical Research, Las Vegas

90301

ADVA Clinical Research, Inc, Inglewood

91303

Hope Clinical Research, Canoga Park

91606

Providence Clinical Research, North Hollywood

92123

TCR Medical Corporation, San Diego

92647

Marvel Research LLC, Huntington Beach

92708

First OC Dermatology, Fountain Valley

97210

ODRC Enterprises, LLC dba Oregon Dermatology and Research Center, Portland

99202

Premier Clinical Research, Spokane

J1L 0H8

Diex Recherche Sherbrooke Inc., Sherbrooke

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT04162769 - A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter